#  <br> M <br> JA <br> The Medical Journal of Australia 

## Supporting Information

## Supplementary methods and results

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix to: Bhattacharyya P, Schemann K, Min SS, et al. Serum vitamin C status of people in New South Wales: retrospective analysis of findings at a public referral hospital. Med J Aust 2023; doi: 10.5694/mja2.52132.

Table 1. Univariable proportional odds ordinal models and Brant test results for the proportional odds assumption

|  | Odds ratio (95\% confidence interval) | Brant test ${ }^{\text {a }}$ |
| ---: | :---: | :---: |
| Year |  | $\chi^{2}=60.4, \mathrm{df}=4, \mathrm{p}<0.001$ |
| 2017 | 1 |  |
| 2018 | $1.28(1.15-1.44)$ |  |
| 2019 | $1.54(1.38-1.72)$ |  |
| 2020 | $1.53(1.38-1.70)$ | $\chi^{2}=10.8, \mathrm{df}=1, \mathrm{p}=0.001$ |
| 2021 | $1.45(1.31-1.61)$ | $\chi^{2}=7.3, \mathrm{df}=1, \mathrm{p}=0.007$ |
|  | $0.98(0.98-0.98)$ | $\chi^{2}=12.3, \mathrm{df}=4, \mathrm{p}=0.016$ |
| Age (per year) | $1.21(1.14-1.30)$ |  |
| Gender (women) |  |  |
| Socio-economic status |  |  |
| (IRSAD quintile) | Q1 | 1 |
| Q2 | $0.91(0.83-1.00)$ |  |
| Q3 | $1.16(1.05-1.27)$ | $\chi^{2}=0.95, \mathrm{df}=3, \mathrm{p}=0.81$ |
| Q4 | $1.30(1.17-1.45)$ |  |
| Q5 -least | $1.66(1.50-1.84)$ |  |
|  |  |  |
| Remoteness | 1 |  |
| Remote/very remote | $1.41(0.94-2.13)$ |  |
| Outer regional | $1.64(1.10-2.46)$ |  |
| Inner regional | $2.17(1.46-3.23)$ |  |
| Major city |  |  |

${ }^{\text {a }}$ The Brant test tests the null hypothesis that the parallel regression/ proportional odds assumption holds. Reference: Brant, R. Assessing proportionality in the proportional odds model for ordinal logistic regression. Biometrics 1990; 46: 1171-1178.

Table 2. Age distribution of 12934 people whose serum vitamin C levels were assessed at the Royal Prince Alfred Hospital, 2017-2021, overall and by vitamin C status

|  | Minimum | Maximum | Mean (SD) | Median (interquartile range) |
| :--- | :---: | :---: | :---: | :---: |
| Normal | 0.0 | 102.0 | $35.8(28.2)$ | $32.0(8.0-62.0)$ |
| Hypovitaminosis C | 0.1 | 102.0 | $46.8(25.7)$ | $51.0(24.0-68.0)$ |
| Significant deficiency | 0.0 | 100.0 | $51.4(23.9)$ | $56.0(36.0-70.0)$ |
| Overall | 0.0 | 102.0 | $42.9(27.3)$ | $47.0(15.0-66.0)$ |

Figure 1. Violin plots of the distribution of the continuous variable Age (in years) overall and by the outcome Vitamin C status in a study of $\mathbf{1 2 , 9 3 4}$ samples


Table 3. Results of two-way interaction testing for Year with Gender added to the main effects only multinomial model for Vitamin C status

|  | Vitamin C status comparison |  |
| :---: | :---: | :---: |
|  | Hypovitaminosis C v Normal | Significant deficiency v Normal |
| Term | Adjusted odds ratio (95\% confidence interval) | Adjusted odds ratio (95\% confidence interval) |
| Model 1 |  |  |
| Age (per year) | 1.02 (1.01-1.02) | 1.02 (1.01-1.02) |
| Year |  |  |
| 2017 | 1 | 1 |
| 2018 | 0.59 (0.47-0.72) | 0.74 (0.58-0.93) |
| 2019 | 0.43 (0.35-0.52) | 0.59 (0.47-0.74) |
| 2020 | 0.42 (0.34-0.51) | 0.47 (0.38-0.58) |
| 2021 | 0.48 (0.40-0.58) | 0.45 (0.36-0.56) |
| IRSAD Quintile |  |  |
| 5th - least disadvantaged | 1 | 1 |
| 4th | 1.2 (1.04-1.39) | 1.41 (1.19-1.67) |
| 3rd | 1.21 (1.06-1.38) | 1.83 (1.57-2.13) |
| 2nd | 1.32 (1.16-1.51) | 2.18 (1.88-2.54) |
| 1st - most disadvantaged | 1.35 (1.19-1.54) | 2.07 (1.79-2.4) |
| Gender |  |  |
| Women | 1 | 1 |
| Men | 0.96 (0.77-1.19) | 1.29 (1.02-1.64) |
| Year: Gender |  |  |
| 2017: Men | 1 | 1 |
| 2018: Men | 0.99 (0.73-1.33) | 1 (0.73-1.38) |
| 2019: Men | 1.16 (0.87-1.56) | 1.01 (0.74-1.38) |
| 2020: Men | 1.25 (0.95-1.66) | 1.12 (0.83-1.53) |
| 2021: Men | 1.25 (0.95-1.64) | 1.15 (0.85-1.56) |

IRSAD = Index of Relative Socio-economic Advantage and Disadvantage.
Interaction testing: Type II Analysis of deviance test:
Year: Gender, likelihood ratio: Chi $s q=6.37, d f=8, p=0.61$.

Table 4. Results of two-way interaction testing for Year with SEIFA IRSAD Disadvantage Quintile added to the main effects only multinomial model for Vitamin C status

|  | Vitamin C status comparison |  |
| :---: | :---: | :---: |
|  | Hypovitaminosis C v Normal | Significant deficiency v Normal |
| Term | Adjusted odds ratio (95\% confidence interval) | Adjusted odds ratio (95\% confidence interval) |
| Age (continuous) | 1.02 (1.01-1.02) | 1.02 (1.02-1.03) |
| Year |  |  |
| 2017 | 1 | 1 |
| 2018 | 0.74 (0.54-1.02) | 0.73 (0.5-1.08) |
| 2019 | 0.48 (0.35-0.67) | 0.60 (0.41-0.88) |
| 2020 | 0.45 (0.33-0.62) | 0.34 (0.23-0.50) |
| 2021 | 0.55 (0.41-0.75) | 0.50 (0.35-0.72) |
| IRSAD quintile |  |  |
| 5th - least disadvantaged | 1 | 1 |
| 4th | 1.70 (1.15-2.50) | 1.47 (0.92-2.33) |
| 3rd | 1.30 (0.93-1.82) | 1.68 (1.14-2.46) |
| 2nd | 1.14 (0.82-1.60) | 1.73 (1.19-2.51) |
| 1st - most disadvantaged | 1.49 (1.08-2.07) | 2.13 (1.48-3.07) |
| Gender |  |  |
| Female | 1 | 1 |
| Male | 1.10 (1.01-1.19) | 1.38 (1.26-1.51) |
| Year: IRSAD quintile (v quintile 5) |  |  |
| 2018: $4^{\text {th }}$ | 0.50 (0.30-0.85) | 0.92 (0.50-1.69) |
| 2019: $4^{\text {th }}$ | 0.68 (0.41-1.15) | 0.96 (0.53-1.74) |
| 2020: $4^{\text {th }}$ | 0.76 (0.47-1.25) | 1.28 (0.70-2.33) |
| 2021: $4^{\text {th }}$ | 0.70 (0.44-1.13) | 0.79 (0.45-1.41) |
| 2018: 3rd | 0.81 (0.51-1.28) | 1.11 (0.66-1.86) |
| 2019:3 ${ }^{\text {rd }}$ | 0.92 (0.58-1.44) | 0.94 (0.56-1.56) |
| 2020:3 ${ }^{\text {rd }}$ | 1.04 (0.67-1.61) | 1.47 (0.88-2.45) |
| 2021:3 $3^{\text {rd }}$ | 0.91 (0.60-1.39) | 1.03 (0.63-1.68) |
| 2018: $2^{\text {nd }}$ | 0.89 (0.56-1.41) | 1.13 (0.68-1.89) |
| 2019: $2^{\text {nd }}$ | 1.19 (0.75-1.88) | 1.16 (0.71-1.91) |
| 2020: $2^{\text {nd }}$ | 1.33 (0.85-2.06) | 1.91 (1.15-3.16) |
| 2021: $2^{\text {nd }}$ | 1.25 (0.82-1.90) | 1.17 (0.73-1.88) |
| 2018: $1^{\text {st }}-$ most | 0.70 (0.45-1.09) | 0.86 (0.53-1.42) |
| 2019: $1^{\text {st }}-$ most | 0.94 (0.61-1.45) | 0.89 (0.55-1.44) |
| 2020: $1^{\text {st }}-$ most | 0.99 (0.65-1.51) | 1.48 (0.90-2.42) |
| 2021: $1^{\text {st }}$ - most | 0.92 (0.60-1.39) | 0.79 (0.49-1.27) |

IRSAD = Index of Relative Socio-economic Advantage and Disadvantage.
Interaction testing - Type II Analysis of deviance test:
Year: Quintile, likelihood ratio: $\mathrm{Chi} \mathrm{sq}=27.1, \mathrm{df}=32, \mathrm{p}=0.72$.

Table 5. Geographic distribution of hypovitaminosis C and significant deficiency test results above 30 per 100000 resident population during 2017-2021 in regional and metropolitan NSW

| SA3 ${ }^{\text {a }}$ | Number with hypovitaminosis C or significant deficiency | Number of tests | Population | Rate per 100000 |
| :---: | :---: | :---: | :---: | :---: |
| Liverpool | 142 | 259 | 125395 | 113.2 |
| Coffs Harbour | 73 | 103 | 88884 | 82.1 |
| Parramatta | 110 | 217 | 151071 | 72.8 |
| Camden | 43 | 82 | 66687 | 64.5 |
| Lithgow - Mudgee | 28 | 53 | 47762 | 58.6 |
| Bringelly - Green Valley | 62 | 112 | 112607 | 55.1 |
| St Marys | 30 | 51 | 56066 | 53.5 |
| Mount Druitt | 62 | 90 | 117192 | 52.9 |
| Tamworth - <br> Gunnedah | 40 | 69 | 82834 | 48.3 |
| Maitland | 29 | 56 | 77800 | 37.3 |
| Blacktown | 51 | 96 | 142159 | 35.9 |
| Richmond - Windsor | 13 | 25 | 37724 | 34.5 |
| Clarence Valley | 17 | 25 | 51266 | 33.2 |
| Gosford | 56 | 113 | 175144 | 32.0 |
| Lower Murray | 4 | 7 | 12785 | 31.3 |

[^0]
[^0]:    ${ }^{\text {a }}$ SA3 $=$ Statistical Area Level 3

